Also known as: SF17 Therapeutics
Synkrino's AI, SATIS is a powerful, unbiased discovery system for…
Company is active
Event Year: 2018
Company is active
Event Year: 2018
Synkrino Biotherapeutics is dedicated to revolutionizing drug discovery through its proprietary artificial intelligence platform, SATIS. This advanced system offers a powerful and unbiased approach to identifying promising therapeutic candidates. By leveraging AI, Synkrino aims to accelerate the development of novel biotherapeutics and address critical unmet needs in the healthcare sector. Their focus is on creating innovative solutions that can significantly improve patient outcomes and transform the future of medicine.
Synkrino Biotherapeutics is dedicated to revolutionizing drug discovery through its proprietary artificial intelligence platform, SATIS. This advanced system offers a powerful and unbiased approach to identifying promising therapeutic candidates. By leveraging AI, Synkrino aims to accelerate the development of novel biotherapeutics and address critical unmet needs in the healthcare sector. Their focus is on creating innovative solutions that can significantly improve patient outcomes and transform the future of medicine.
Total Raised: Unknown (Y Combinator backed)
Last Round: Summer 2018
Total Raised: Unknown (Y Combinator backed)
Last Round: Summer 2018
Healthcare
Healthcare
Healthcare -> Drug Discovery and Delivery
Healthcare -> Drug Discovery and Delivery
Team size: 2
Hiring: No
Team size: 2
Hiring: No
